NCT05843253 2026-04-22
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
Clinical Trials
665 trialsNCT07544992 2026-04-22
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT07462507 2026-04-21
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Washington University School of Medicine
Phase 2 Recruiting
NCT05698524 2026-04-17
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
Phase 1 Recruiting
NCT00268385 2026-04-13
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01089101 2026-04-13
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02381886 2026-04-13
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Phase 1 Active not recruiting
NCT02800486 2026-04-13
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
Phase 2 Recruiting
NCT03528642 2026-04-13
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03581292 2026-04-13
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03911388 2026-04-13
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03919071 2026-04-13
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04145115 2026-04-13
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06860594 2026-04-13
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
Phase 1 Suspended
NCT07468136 2026-04-13
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Mayo Clinic
Phase 1/2 Not yet recruiting
NCT06344130 2026-04-09
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07301268 2026-04-08
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Phase 2 Recruiting
NCT07089641 2026-04-07
ERAS801-SARG
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT04978727 2026-04-06
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
Phase 1 Active not recruiting
NCT03975829 2026-04-02
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Active not recruiting
NCT05789394 2026-04-02
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Mayo Clinic
Phase 1 Recruiting
NCT07417761 2026-04-02
TUVASTRAT
Grupo Español de Investigación en Neurooncología
Phase 2 Recruiting
NCT04729959 2026-04-01
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05839379 2026-03-31
Targeted Pediatric High-Grade Glioma Therapy
Nationwide Children's Hospital
Recruiting
NCT06809322 2026-03-31
VIGOR
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT03596086 2026-03-30
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
The Methodist Hospital Research Institute
Phase 1/2 Recruiting
NCT03603405 2026-03-30
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
The Methodist Hospital Research Institute
Phase 1/2 Recruiting
NCT04197934 2026-03-30
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Mayo Clinic
Phase 1 Active not recruiting
NCT05765812 2026-03-30
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
Phase 1/2 Recruiting
NCT02851706 2026-03-27
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
National Institutes of Health Clinical Center (CC)
Completed
NCT03796273 2026-03-20
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
Wake Forest University Health Sciences
Phase EARLY_PHASE1 Terminated
NCT05577416 2026-03-18
AB-218-IIT-201
Melbourne Health
Phase EARLY_PHASE1 Completed
NCT05393258 2026-03-17
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas
Washington University School of Medicine
Phase NA Completed
NCT05417594 2026-03-12
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT05484622 2026-03-12
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Servier
Phase 1 Active not recruiting
NCT06333899 2026-03-12
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Nationwide Children's Hospital
Phase EARLY_PHASE1 Recruiting
NCT06894979 2026-03-12
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
Phase 1 Recruiting
NCT03896568 2026-03-05
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05303519 2026-03-05
SIGMA
Nuvation Bio Inc.
Phase 3 Recruiting
NCT03152318 2026-03-04
rQNestin
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT07448480 2026-03-04
GLIOTARG
Blokhin's Russian Cancer Research Center
Active not recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT06665724 2026-02-27
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Universität Münster
Phase 1 Completed
NCT07439172 2026-02-27
PRC
The Cooper Health System
Phase 2 Not yet recruiting
NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT05345002 2026-02-20
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT03450850 2026-02-17
Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma
University of California, Irvine
Phase NA Completed
NCT05957679 2026-02-12
MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment
Shengjing Hospital
Phase NA Recruiting
NCT04923126 2026-02-04
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting